(4R)-1-[5-chloro-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-L-prolinamide | 905077-26-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4R)-1-[5-chloro-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-L-prolinamide
• 英文别名: (2S,4R)-1-[5-Chloro-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxypyrrolidine-2-carboxylic acid dimethylamide；(2S,4R)-1-(5-Chloro-3-(2-methoxyphenyl)-2-oxoindolin-3-YL)-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide；(2S,4R)-1-[5-chloro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide
• CAS: 905077-26-1
• 化学式: C₂₂H₂₄ClN₃O₄
• 分子量: 429.903
• InChiKey: WRNVMCWBWWYGLM-RZOYMLOVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  82.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4R)-1-[5-chloro-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-L-prolinamide 、 2,5-二(2,2,2-三氟乙氧基)-苯磺酰氯 以119 mg of the title compound (colorless amorphous) was obtained by a similar method to Example 2的产率得到(4R)-1-[1-{[2,5-bis(2,2,2-trifluoroethoxy)phenyl]sulfonyl}-5-chloro-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-in dol-3-yl]-4-hydroxy-N,N-dimethyl-L-prolinamide
  参考文献：
  名称：

  1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle

  摘要：

  本发明旨在提供一种对精氨酸加压素V1b受体相关的病理状况有效的药物。更具体地说，本发明旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、饮食失调、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫性疾病、脱发等具有治疗或预防作用的药物。经过密集研究，发现了一种新型的1,3-二氢吲哚-2-酮化合物和一种与杂环芳香环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性、良好的脑穿透性和高血浆浓度，从而实现了上述目标。

  公开号：

  US08030499B2
• 作为产物：
  描述：

  3,5-dichloro-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one 、 (4R)-4-羟基脯氨酸-N,N-二甲基酰胺盐酸盐 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (4R)-1-[5-chloro-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-L-prolinamide 、 (4R)-1-[5-chloro-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-L-prolinamide
  参考文献：
  名称：

  Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them

  摘要：

  本发明涉及新颖的1,3-二氢吲哚-2-酮（氧吲哚）衍生物，其化学式为（I），其中A、R3、R4、R5、R6和R7根据权利要求1中的定义，并且含有这些衍生物的药物用于治疗疾病。特别是，这些新型氧吲哚衍生物可用于控制和/或预防各种依赖于加压素或催产素的疾病。

  公开号：

  US20050070718A1

文献信息

• 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
  申请人：Sekiguchi Yoshinori

  公开号：US20080318923A1

  公开（公告）日：2008-12-25

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  旨在提供一种对与精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说，旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫疾病、脱发等具有治疗或预防作用的药物。经过深入研究，发现了一种新颖的1,3-二氢-2H-吲哚-2-酮化合物和与杂芳环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性，表现出有利的血脑屏障穿透和高血浆浓度，从而实现了上述目标。
• Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them
  申请人：——

  公开号：US20040209938A1

  公开（公告）日：2004-10-21

  The invention relates to compounds of formula: 1 as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V 1b receptors or towards both the V 1b and V 1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.

  本发明涉及以下式子的化合物1，以及可能的与矿物质或有机酸形成的盐，以及溶剂化合物和/或水合物，这些化合物对精氨酸加压素的V1b受体或V1b和V1a受体都具有亲和力和选择性。本发明还涉及制备它们的方法，有用于制备它们的式子(II)的中间体化合物，含有它们的制药组合物以及它们用于制备药物的用途。
• Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors
  申请人：——

  公开号：US20030114683A1

  公开（公告）日：2003-06-19

  The invention relates to compounds of formula: 1 as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V 1b receptors or towards both the V 1b and V 1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.

  本发明涉及以下化合物的公式：1，以及可能的与矿物质或有机酸盐和其溶剂和/或水合物，这些化合物具有亲和力和选择性，可以作用于精氨酸加压素的V1b受体或V1b和V1a受体。本发明还涉及制备它们的过程，有用于制备它们的公式（II）的中间化合物，包含它们的制药组合物以及它们用于制备药物的用途。
• NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Roux Richard

  公开号：US20070004703A1

  公开（公告）日：2007-01-04

  The invention relates to compounds of formula: as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V 1b receptors or towards both the V 1b and V 1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.

  本发明涉及式的化合物：以及其可能的与矿物酸或有机酸形成的盐，以及其溶剂化合物和/或水合物，其具有亲和力和选择性，能够作用于精氨酸加压素的V1b受体或V1a和V1b受体。本发明还涉及用于制备它们的过程，有用于制备它们的式（II）的中间体化合物，含有它们的制药组合物以及它们用于制备药物的用途。
• Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing Them
  申请人：Lubisch Wilfried

  公开号：US20070185126A1

  公开（公告）日：2007-08-09

  The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R 3 , R 4 , R 5 R 6 and R 7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.

  本发明涉及式(I)的新型1,3-二氢吲哚-2-酮（氧化吲哚）衍生物，其中A、R3、R4、R5R6和R7如权利要求1所定义，并且包含它们的药物用于治疗疾病。特别地，这些新型氧化吲哚衍生物可用于控制和/或预防各种依赖于加压素或催产素的疾病。